Biotech

All Articles

8 months after a $213M fundraise, gene editor Volume helps make cuts

.After bring up $213 thousand in 2023-- one of the year's largest private biotech rounds-- Tome Bios...

BioMarin builds officer team along with biotech vets-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and ...

Biopharma Q2 VC struck highest level since '22, while M&ampA slowed

.Equity capital financing right into biopharma rose to $9.2 billion across 215 sell the 2nd one-four...

Bicara, Zenas find IPOs to push late-phase properties towards market

.Bicara Rehabs and also Zenas Biopharma have provided clean catalyst to the IPO market with filings ...

Genentech to close cancer immunology study department

.Genentech will close its cancer cells immunology research department, and device head as well as pr...

Kezar goes down strong growth however to show its own well worth in stage 1 trial

.Kezar Lifestyle Sciences is losing its own unpromising phase 1 strong lump medicine as the biotech ...

Acelyrin falls izokibep, dismisses 3rd of personnel

.Even with izokibep maintaining its newly found winning touch in the clinic, Acelyrin is actually no...

Rivus' stage 2 obesity-related cardiac arrest test strikes endpoint

.Rivus Pharmaceuticals has plumped up the leads of its own fat-busting, muscle-sparing drug candidat...

Ovid halts preclinical work, IV course after soticlestat stop working

.Ovid Therapeutics actually showed final month that it was trimming its headcount as the company nav...

Eli Lilly opens up $700M nucleic acid R&ampD center in Boston Seaport

.Eli Lilly has opened up a $700 million R&ampD facility in the Boston ma Port, increasing its own RN...